Shared on 01 Nov 25
Fair value Increased 12%Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.
Shared on 18 Oct 25
Fair value Increased 6.82%Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.
Shared on 30 Aug 25
Fair value Increased 14%The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.
Shared on 01 Aug 25
Fair value Decreased 22%The notable downward revision in NeoGenomics’ analyst price target reflects reduced revenue growth forecasts and a lower forward P/E, resulting in a new fair value estimate of $8.72. What's in the News Launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling test for noninvasive therapy selection and monitoring, expanding presence in the $3-5 billion liquid biopsy market.
Shared on 17 Apr 25
Fair value Decreased 3.85%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 1.64%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Increased 68%AnalystConsensusTarget made no meaningful changes to valuation assumptions.